Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Biogen reported for 6 months of 2023

7/25/23 BIIB

Positive Technologies reported for 6 months of 2023 by IFRS

7/25/23 POSI

General Motors reported for 6 months of 2023

7/25/23 GM

3M reported for 6 months of 2023

7/25/23 MMM

PulteGroup reported for 6 months of 2023

7/25/23 PHM

General Electric reported for 6 months of 2023

7/25/23 GE

Spotify has reported for Q2 2023

7/25/23 SPOT

Chizhik discounter chain continues expansion in southern regions of Russia

7/25/23 -

RuStore opened application monetization for foreign developers

7/25/23 VKCO

Red October reported for 6 months of 2023 by RAS

7/25/23 KROT